10 essential updates for Breast Cancer Awareness Month

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Breast Cancer Awareness Month is observed every October.

The international health campaign is designed to increase awareness of the disease and raise money to fund research for prevention, earlier detection and more effective treatment.

In conjunction with this observance, HemOnc Today and Healio highlight 10 research updates in breast cancer treatment, diagnosis, prevention and survivorship.

• The addition of abemaciclib (Verzenio, Eli Lilly) to fulvestrant significantly prolonged OS among women with hormone receptor-positive, HER2-negative advanced breast cancer whose disease progressed following endocrine therapy. Read more.
• Proton beam radiation therapy for breast cancer appeared safe and conferred similar rates of disease control compared with historical data of conventional radiation therapy. Read more.
• Women who underwent combined breast, plastic reconstructive and gynecologic surgery exhibited higher rates of postoperative complications, readmission and reoperation than women who underwent breast surgery alone. Read more.
• The addition of pembrolizumab (Keytruda, Merck) to neoadjuvant chemotherapy significantly increased the pathologic complete response rate among patients with early-stage triple-negative breast cancer. Read more.
• Men at high risk for breast cancer may benefit from screening for the disease. Read more.
• Young survivors of breast cancer face higher risk for late congestive heart failure than their counterparts without cancer. Read more.
• The addition of ribociclib (Kisqali, Novartis) to fulvestrant significantly extended OS among postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. Read more.
• Dexrazoxane reduced the risk for cardiac events and clinical heart failure among women with breast cancer who underwent anthracycline chemotherapy. Read more.
• Use of hormone replacement therapy may increase risk for lung cancer as a second primary malignancy among patients with breast cancer who smoke. Read more.
• The U.S. Preventive Services Task Force recommended that clinicians offer breast cancer risk-reducing medications such as tamoxifen, raloxifene and aromatase inhibitors to asymptomatic women aged 35 years and older who are at elevated risk for developing the disease and low risk for adverse effects from the treatments. Read more.